Nancy Friend Pritzker Psychiatry Building, University of California, San Francisco
San Francisco, California, 94107, United States
NCT Number: NCT06580041
This study aims to assess whether phenotyping-guided intervention selection is superior to intervention selection without phenotyping guidance (i.e., routine clinician and patient judgment regarding treatment selection) for depression.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 4
San Francisco, California, 94107, United States
This study will classify patients seen in the Depression Clinic of the UCSF Department of Psychiatry and Behavioral Sciences into one of five phenotypes (subtypes), including: 1) Anhedonia, 2) Cognitive deficits, 3) Stress sensitivity, 4) Anxious distress, and 5) Grief.
After phenotyping, participants will be randomized to receive phenotype-specific intervention (PSI) or care as usual (CAU).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
CAU plan modified to include a trial of pramipexole.
CAU plan modified to include a trial of methylphenidate (or, if contraindicated: guanfacine).
CAU plan modified to include a trial of phenelzine (or, if contraindicated: brexpiprazole).
CAU plan modified to include a trial of MBSST. MBSST is an individual psychotherapy delivered approximately weekly for 16 sessions.
CAU plan modified to include a trial of CGT.
Unmodified CAU plan.
Time frame: Up to 24 weeks after randomization.
Within-phenotype and across-phenotype contrasts.
Time frame: Up to 24 weeks after randomization.
For anhedonia phenotype only.
Time frame: Up to 24 weeks after randomization.
For anxious distress phenotype only.
Time frame: Up to 24 weeks after randomization.
For anxious distress phenotype only.
Time frame: Up to 24 weeks after randomization.
For grief phenotype only.
Time frame: Up to 24 weeks after randomization.
For cognitive deficits phenotype only.
Time frame: Up to 24 weeks after randomization.
Within-phenotype and across-phenotype contrasts.
Time frame: Up to 24 weeks after randomization.
Within-phenotype and across-phenotype contrasts.
Time frame: Up to 24 weeks after randomization.
50% reduction from baseline score. Within-phenotype and across-phenotype contrasts.
Time frame: Up to 24 weeks after randomization.
Score < 6. Within-phenotype and across-phenotype contrasts.
University of California, San Francisco
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03288714
Behavior, Behavioral Symptoms
La Jolla, California, United States
View Trial DetailsNCT03932825
Behavior, Behavioral Symptoms
Changsha, Hunan, China
View Trial DetailsNCT02407704
Behavior, Behavioral Symptoms
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT03736538
Behavior, Behavioral Symptoms
St Louis, Missouri, United States
View Trial Details